• 1
    Cota D, Proulx K, Smith KA, Kozma SC, Thomas G, Woods SC et al . Hypothalamic mTOR signaling regulates food intake. Science 2006;312:927930.
  • 2
    Dann SG, Selvaraj A, Thomas G. mTOR ComplepagerangeK1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med 2007;13:252259.
  • 3
    Manning BD. Balancing Akt with S6 K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 2004;167:399403.
  • 4
    Khamzina L, Veilleux A, Bergeron S, Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology 2005;146:14731481.
  • 5
    Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95105.
  • 6
    Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS et al . A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994;369:756758.
  • 7
    Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998;31:335340.
  • 8
    Cowan PA, Heizer KE. Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection. Nephrol Nurs J 2000;27:623625.
  • 9
    Morrisett JD, Abdel-Fattah G., Kahan BD. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 2003;35:S143S150.
  • 10
    Garber K. Rapamycin's resurrection: a new way to target the cancer cell cycle. J Natl Cancer Inst 2001;93:15171519.
  • 11
    Thomas GV. mTOR and cancer: reason for dancing at the crossroads? Curr Opin Genet Dev 2006;16:7884.
  • 12
    Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C et al . Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2004;349:13151323.
  • 13
    Serruys PW, Regar E, Carter AJ. Rapamycin eluting stent: the onset of a new era in interventional cardiology. Heart 2002;87:305307.
  • 14
    Lo A. Immunosuppression and metabolic syndrome in renal transplant recipients. Metab Syndr Relat Disord 2004;2:263273.
  • 15
    Soliman GA. The mammalian target of rapamycin signaling network and gene regulation. Curr Opin Lipidol 2005;16:317323.
  • 16
    Bodary PF, Vargas FB, King SA, Jongeward KL, Wickenheiser KJ, Eitzman DT. Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. J Thromb Haemost 2005;3:21492153.
  • 18
    Suto J, Matsuura S, Imamura K, Yamanaka H, Sekikawa K. Genetic analysis of non-insulin-dependent diabetes mellitus in KK and KK-Ay mice. Eur J Endocrinol 1998;39:654661.
  • 17
    Chen WY, Chen CJ, Liu CH, Mao FC. Chromium supplementation enhances insulin signalling in skeletal muscle of obese KK/HIJ diabetic mice. Diabetes Obes Metab 2009;11:293303.
  • 19
    Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 2002;15:72917297.
  • 20
    Namba R, Young LJ, Abbey CK, Kim L, Damonte P, Borowsky AD et al . Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clin Cancer Res 2006;12:26132621.
  • 21
    Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ et al . Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003;107: 16641670.
  • 22
    Kwon YS, Hong HS, Kim JC, Shin JS, Son Y. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest Ophthalmol Vis Sci 2005;46:454460.
  • 23
    Chodera A, Feller K. Some aspects of pharmacokinetic and biotransformation differences in humans and mammal animals. Int J Clin Pharmacol Biopharm 1978;16:357360.
  • 24
    Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int 2001;59:316.
  • 25
    Chen YB, Sun YA, Gong JP. Effects of rapamycin in liver transplantation. Hepatobiliary Pancreat Dis Int 2008;7:2528.
  • 26
    Cornelli U, Terranova R, Luca S, Cornelli M, Alberti A. Bioavailability and antioxidant activity of some food supplements in men and women using the D-Roms test as a marker of oxidative stress. J Nutr 2001;131:32083211.
  • 27
    Folch J, Lees M, Stanley GHS. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957;226:497509.
  • 28
    Bluher M, Wilson-Fritch L, Leszyk J, Laustsen PG, Corvera S, Kahn CR. Role of insulin action and cell size on protein expression patterns in adipocytes. J Biol Chem 2004;279:3190231909.
  • 29
    Gilat T, Leikin-Frenkel A, Goldiner I, Juhel C, Lafont H, Gobbi D et al . Prevention of diet-induced fatty liver in experimental animals by the oral administration of a fatty acid bile acid conjugate (FABAC). Hepatology 2003;38:436442.
  • 30
    Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007;12:487502.
  • 31
    Cota D, Matter EK, Woods SC, Seeley RJ. The role of hypothalamic mammalian target of rapamycin complex 1 signaling in diet-induced obesity. J Neurosci 2008;28:72027208.
  • 32
    Heid HW, Moll R, Schwetlick I, Rackwitz HR, Keenan TW. Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases. Cell Tissue Res 1998;294:309321.
  • 33
    Larigauderie G, Cuaz-Pérolin C, Younes AB, Furman C, Lasselin C, Copin C et al . Adipophilin increases triglyceride storage in human macrophages by stimulation of biosynthesis and inhibition of β-oxidation. FEBS J 2006;273:34983510.
  • 34
    Chang BH, Li L, Paul A, Taniguchi S, Nannegari V, Heird WC et al . Protection against fatty liver but normal adipogenesis in mice lacking adipose differentiation-related protein. Mol Cell Biol 2006;26:10631076.
  • 35
    Larigauderie G, Furman C, Jaye M, Lasselin C, Copin C, Fruchart JC et al . Adipophilin enhances lipid accumulation and prevents lipid efflux from THP-1 macrophages: potential role in atherogenesis. Arterioscler Thromb Vasc Biol 2004;24:504510.
  • 36
    Sipula IJ, Brown NF, Perdomo G. Rapamycin-mediated inhibition of mammalian target of rapamycin in skeletal muscle cells reduces glucose utilization and increases fatty acid oxidation. Metabolism 2006;55:16371644.
  • 37
    Newberry EP, Xie Y, Kennedy SM, Luo J, Davidson NO. Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. Hepatology 2006;44:11911205.
  • 38
    Westerbacka J, Lammi K, Hakkinen AM, Rissanen A, Salminen I, Aro A et al . Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005;90:28042809.
  • 39
    Mine T, Miura K, Kajioka T, Kitahara Y. Nateglinide prevents fatty liver through up-regulation of lipid oxidation pathway in Goto-Kakizaki rats on a high-fat diet. Metabolism 2008;57:140148.
  • 40
    Schieke SM, Phillips D, McCoy JPJr, Aponte AM, Shen RF, Balaban RS et al . The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J Biol Chem 2006;281:2764327652.
  • 41
    Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 2007;450:736740.
  • 42
    Mauvoisin D, Rocque G, Arfa O, Radenne A, Boissier P, Mounier C. Role of the PI3-kinase/mTor pathway in the regulation of the stearoyl CoA desaturase (SCD1) gene expression by insulin in liver. J Cell Commun Signal 2007;1:113125.
  • 43
    Imai Y, Varela GM, Jackson MB, Graham MJ, Crooke RM, Ahima RS. Reduction of hepatosteatosis and lipid levels by an adipose differentiation-related protein antisense oligonucleotide. Gastroenterology 2007;132:19471954.
  • 44
    Rosenbaum M, Leibel RL, Hirsch J. Obesity. N Engl J Med 1997;337:396407.
  • 45
    Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000;404:661671.
  • 46
    Della Zuana O, Sadlo M, Germain M, Félétou M, Chamorro S, Tisserand F et al . Reduced food intake in response to CGP 71683A may be due to mechanisms other than NPY Y5 receptor blockade. Int J Obes 2001;25:8494.
  • 47
    Villafuerte BC, Fine JB, Bai Y, Zhao W, Fleming S, DiGirolamo M. Expressions of leptin and insulin-like growth factor-I are highly correlated and region-specific in adipose tissue of growing rats. Obes Res 2000;8:646655.
  • 48
    Baeder WL, Sredy J, Sehgal SN, Chang JY, Adams LM. Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Clin Exp Immunol 1992;89:174178.
  • 49
    Briaud I, Dickson LM, Lingohr MK, McCuaig JF, Lawrence JC, Rhodes CJ. Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in β-cells. J Biol Chem 2005;280:22822293.
  • 50
    Tzatsos A, Kandror KV. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 2006;26:6376.
  • 51
    Pende M, Kozma SC, Jaquet M, Oorschot V, Burcelin R, Le Marchand-Brustel Y et al . Hypoinsulinaemia, glucose intolerance and diminished β-cell size in S6K1-deficient mice. Nature 2000;408:994997.
  • 52
    Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M et al . Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004;431:200205.
  • 53
    Chang GR, Chiu YS, Wu YY, Chen WY, Liao JW, Chao TH et al . Rapamycin protects against high fat diet-induced obesity in C57BL/6J mice. J Pharmacol Sci 2009;109:496503.
  • 54
    Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, Castel J et al . mTOR inhibition by rapamycin prevents β-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008;57:945957.
  • 55
    Di Paolo S, Teutonico A, Leogrande D, Capobianco C, Schena PF. Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes? J Am Soc Nephrol 2006;17:22362244.
  • 56
    Dandona P, Mohanty P, Ghanim H, Aljada A, Browne R, Hamouda W et al . The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. J Clin Endocrinol Metab 2001;86:355362.
  • 57
    McClung JP, Roneker CA, Mu W, Lisk DJ, Langlais P, Liu F et al . Development of insulin resistance and obesity in mice overexpressing cellular glutathione peroxidase. Proc Natl Acad Sci USA 2004;101:88528857.
  • 58
    Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y et al . Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:17521761.
  • 59
    Mauriège P, Imbeault P, Langin D, Lacaille M, Alméras N, Tremblay A et al . Regional and gender variations in adipose tissue lipolysis in response to weight loss. J Lipid Res 1999;40:15591571.
  • 60
    Medina J, Fernández-Salazar LI, García-Buey L, Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004;27:20572066.
  • 61
    Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 2000;85:29702973.
  • 62
    Welle S, Lilavivathana, U, Campbell RG. Increased plasma norepinephrine concentrations and metabolic rates following glucose ingestion in man. Metabolism 1980;29:806809.
  • 63
    Alsharif NZ, Hassoun EA. Protective effects of vitamin A and vitamin E succinate against 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced body wasting, hepatomegaly, thymic atrophy, production of reactive oxygen species and DNA damage in C57BL/6J mice. Basic Clin Pharmacol Toxicol 2004;95:131138.
  • 64
    Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002;23:599622.
  • 65
    Rösen P, Nawroth PP, King G, Möller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001;17:189212.
  • 66
    Mathis AS, Dave N, Knipp GT, Friedman GS. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 2004;61:565585.
  • 67
    Reuben A. Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity. Liver Transpl 2001;7:S13S21.